Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Carmine De Angelis, Carmen Criscitiello et al.|EClinicalMedicine|2025Cited by 7
Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-AnalysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|SSRN Electronic Journal|2025Cited by 0